Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists
AssigneeNovartis AG
InventorsDominik Feuerbach, Konstanze Hurth, Timothy John Ritchie, Rochdi Bouhelal
Life of this patent
Estimating the term…
Abstract
The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
Claims5
A method for the treatment of a disease or disorder in a subject in need of such treatment, the method comprising:
- administering to the subject a therapeutically effective amount of a selective α7 nicotinic acetylcholine receptor (nAChR) agonist,
- wherein the selective α7 nAChR agonist is (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane in free base form or in acid addition salt form, and
- wherein the disease or disorder is schizophrenia.
A method for promoting cessation of smoking in a subject in need of such treatment, the method comprising:
- administering to the subject a therapeutically effective amount of a selective α7 nicotinic acetylcholine receptor (nAChR) agonist, wherein the selective α7 nAChR agonist is (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane in free base form or in acid addition salt form.
A pharmaceutical composition comprising:
- (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane in free base form or in acid addition salt form as an active pharmaceutical ingredient;
- and
- a pharmaceutical carrier or diluent,
- wherein the pharmaceutical composition comprises about 0.1% to about 99.9% active pharmaceutical ingredient by weight.
Dependencies are inferred from the claim text.